Jacqueline M. Greer

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

Ivana Gojo, Anchalee Jiemjit, Jane B. Trepel et al. · Blood · 2006 · 282 citations · Full text

Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias

Judith E. Karp, Ivana Gojo, Christopher D. Gocke et al. · Clinical Cancer Research · 2004 · 178 citations

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib et al. · Blood · 2006 · 173 citations · Full text

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

Judith E. Karp, B M Thomas, Jacqueline M. Greer et al. · Clinical Cancer Research · 2012 · 117 citations · Full text

A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

Judith E. Karp, Francis J. Giles, Ivana Gojo et al. · Leukemia Research · 2007 · 98 citations · Full text

Hematological Malignancy, Oncology, Nucleoside Analog Fludarabine +9